Stockscreener 앱 받기
0.00
100.00%
-13.85
전일 마감가:
$13.85
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$18.59M
수익:
-
순이익/손실:
$-24.14M
주가수익비율:
0.00
EPS:
-13.985
순현금흐름:
$-22.40M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$16.52
52주 변동 폭
$0.00
$36.76
센세이 바이오테라 Stock (SNSE) Company Profile
명칭
Faeth Therapeutics Inc
전화
(240) 243-8000
주소
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare SNSE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNSE
Faeth Therapeutics Inc
|
0.00 | 18.59M | 0 | -24.14M | -22.40M | -13.98 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
센세이 바이오테라 Stock (SNSE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-20 | 개시 | Leerink Partners | Outperform |
| 2025-06-02 | 재개 | H.C. Wainwright | Buy |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2021-07-01 | 다운그레이드 | Berenberg | Buy → Hold |
| 2021-06-29 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-01 | 개시 | Berenberg | Buy |
| 2021-03-01 | 개시 | Citigroup | Buy |
| 2021-03-01 | 개시 | Oppenheimer | Outperform |
| 2021-03-01 | 개시 | Piper Sandler | Overweight |
모두보기
센세이 바이오테라 주식(SNSE)의 최신 뉴스
Faeth Therapeutics Launches New At-the-Market Equity Program - The Globe and Mail
Faeth Therapeutics, Inc. Enters At-The-Market Sales Agreement with TD Securities to Sell Common Stock on Nasdaq - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Faeth Therapeutics Launches $150 Million ATM Stock Offering With TD Securities - TradingView
Faeth Therapeutics (NASDAQ: SNSE) launches $150M at-the-market stock program - Stock Titan
Faeth Therapeutics (NASDAQ: FTH) launches $150M ATM sales agreement with TD Cowen - Stock Titan
FTH Price Today: Faeth Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
EBITDA per share of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Return on assets % of Faeth Therapeutics, Inc. – BOATS:FTH - TradingView
Price to cash flow ratio of Faeth Therapeutics, Inc. – BOATS:FTH - TradingView
Faeth Therapeutics, Inc.: Shareholders Board Members Managers and Company Profile | US81728A2078 - marketscreener.com
Non-controlling/minority interest of Faeth Therapeutics, Inc. – BOATS:FTH - TradingView
Faeth Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | FTH | US81728A2078 - marketscreener.com
Faeth Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | 4070 | US81728A2078 - marketscreener.com
Faeth Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | FTH | US81728A2078 - marketscreener.com
Faeth Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | FTH | US81728A2078 - marketscreener.com
FTH: Static price chart | Faeth Therapeutics, Inc. | US81728A2078 - marketscreener.com
Faeth Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | FTH | US81728A2078 - marketscreener.com
Faeth Therapeutics, Inc.: Performance & Quotes, FTH Stock Price on Nasdaq Exchange - marketscreener.com
Faeth Therapeutics, Inc. Stock (FTH)Quote Nasdaq - marketscreener.com
FTH (Faeth Therapeutics) Cyclically Adjusted PS Ratio : (As of Jun. 17, 2026) - GuruFocus
Faeth Therapeutics Inc (FTH) Stock Earnings Transcripts - GuruFocus
Faeth Therapeutics, Inc. (FTH) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Faeth Therapeutics, Inc. (FTH) Stock Live Price, Chart & News - CoinCodex
Total liabilities of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Operating income of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Total revenue of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Director at Sensei Biotherapeutics (NASDAQ: SNSE) awarded 25,000 stock options - Stock Titan
Net current asset value per share of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Enterprise value to EBITDA ratio of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Sensei Biotherapeutics (SNSE) CEO converts Series B preferred into 761,428 common shares - Stock Titan
Director Ramasastry lists merger-based options in Sensei Biotherapeutics (SNSE) - Stock Titan
Net debt of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Director at Sensei Biotherapeutics (NASDAQ: SNSE) gains shares, options - Stock Titan
Sensei Biotherapeutics (SNSE) director reports Series B preferred stake from merger - Stock Titan
Diluted earnings per share (diluted EPS) of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Total debt of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
EBIT of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Free cash flow of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Free float of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Net income of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Dilution adjustment of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Faeth Therapeutics, Inc. Balance Sheet – NASDAQ:FTH - TradingView
Operating expenses (excl. COGS) of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Faeth Therapeutics, Inc. Cash Flow – NASDAQ:FTH - TradingView
Basic earnings per share (basic EPS) of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Net margin % of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Total operating expenses of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Cash per share of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Discontinued operations of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
After tax other income/expense of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
센세이 바이오테라 (SNSE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):